Claims for Patent: 6,908,907

Summary for Patent: 6,908,907

Title:	Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients
Abstract:	This invention provides for the prevention and treatment of tumor growth, metastasis, and cancer-mediated thrombosis through the administration, in combination, of a short or long acting GPIIb/IIIa antagonist (A) and anticoagulant (B) that might include the following: UFH or low molecular weight heparin, (LMWH), ultra LMWH, pentasaccharide or direct anti-Xa or direct anti-IX/IXa, direct anti-IIa (thrombin) or tissue factor pathway inhibitor (TFPI) by any means that produces contact of the agents with their site of action wherein at least one of the components of each of these combinations is given in reduced amount. This combined formulation could be used as a stand-alone regimen or in conjunction with other therapies (chemotherapy, radiotherapy, angiogenesis inhibitors, . . . ), and pre- & post-tumor surgery in the prevention and treatment of cancer associated metastasis, angiogenesis, tumor growth, and thrombosis.
Inventor(s):	EL-Naggar; Mawaheb M. (Lincoln Univ., PA), Mousa; Shaker A. (Lincoln Univ., PA)
Assignee:
Application Number:	10/125,882
Patent Claims:	1. A method, comprising treating tumor growth and metastasis in a mammal, said treating including administering a composition to the mammal, said composition comprising a sub-therapeutic dose of a GPIIb/IIIa antagonist, a sub-therapeutic dose of an anticoagulant, and a polycationic carbohydrate, wherein the anticoagulant comprises unfractionated heparin (UFH), low molecular weight heparin (LMWH), ultra LMWH, or pentasaccharide. 2. The method of claim 1, wherein the LMWH is selected from the group consisting of tinzaparin, certoparin, parnaparin, nadroparin, ardeparin, enoxaparin, reviparin, reviparin, dalteparin, and fraxiparin. 3. The method or claim 1, wherein the GPIIb/IIIa antagonist is selected from the group consisting of Abciximab, XV459), DMP754 (Roxifiban), DMP802, and XV454. 4. The method of claim 1, wherein the anticoagulant comprises direct anti-Xa. 5. The method of claim 1, wherein the anticoagulant comprises anti-IX/Xa. 6. The method of claim 1, wherein the anticoagulant comprises direct anti-IIa (thrombin). 7. The method of claim 1, wherein the anticoagulant comprises direct anti-VIIa. 8. The method of claim 1, wherein the anticoagulant comprises anti-tissue factor. 9. The method of claim 1, wherein the mammal is a human cancer patient. 10. A method, comprising treating tumor growth and metastasis in a mammal, said treating including administering a composition to the mammal, said composition comprising a sub-therapeutic dose of a GPIIb/IIIa antagonist, a sub-therapeutic dose of an anticoagulant, and a polycationic peptide, wherein the anticoagulant comprises unfractionated heparin (UFH), low molecular weight heparin (LMWH, ultra LMWH, or pentasaccharide. 11. The method of claim 10, wherein the GPIIb/IIIa antagonist is selected from the group consisting pf Abciximab, XV459, DMP754 (Roxifiban), DMP802, and XV454. 12. The method of claim 10, wherein the anticoagulant comprises direct anti-Xa. 13. The method of claim 10, wherein the anticoagulant comprises anti-IX/IXa. 14. The method of claim 10, wherein the anticoagulant comprises direct anti-IIa (thrombin). 15. The method of claim 10, wherein the anticoagulant comprises anti-VIIa. 16. The method of claim 10, wherein the anticoagulant comprises anti-tissue factor. 17. The method of claim 10, wherein the mammal is a human cancer patient.

Details for Patent 6,908,907

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2039-03-29